Odronextamab is a CD20xCD3 bispecific antibody used to treat adults with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).
- Mechanism
- Curator reviewed · 3 references
Odronextamab is a human IgG4-based bispecific antibody that binds to CD20 - a B-cell surface antigen present on normal and malignant B cells - and CD3 - a T-cell antigen associated with the T-cell receptor complex. Simultaneous engagement of both arms of odronextamab results in formation of a synapse between the T cell and the CD20 expressing cell, resulting in T-cell activation and generation of polyclonal cytotoxic T-cell response. Odronextamab ultimately causes targeted B-cell lysis and cell death.
- Primary indication
- Odronextamab is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy.Curator reviewed · 4 structured indications
- Formula / weight
- C6458H9950N1728O2020S46 · 145591.54 Da
- First approval
- European Union, 2025
- Also known as
- Anti-CD20/CD3 monoclonal antibody REGN1979
- Code names
- REGN-1979 · WHO 11035
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Odronextamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account